Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03866603 · ClinicalTrials.gov registry record

Rostock International Parkinson's Disease Study (ROPAD)

A clinical trial of Parkinson's Disease, sponsored by CENTOGENE GmbH Rostock.

Active
Registry status
25,000
Enrollment target
20
Study locations

NCT03866603 is a study of Parkinson's Disease that is active but no longer recruiting, run by CENTOGENE GmbH Rostock. The registered enrollment target is 25,000 participants, above the 482-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (5087% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03866603, a study of Parkinson's Disease, is active but no longer recruiting, sponsored by CENTOGENE GmbH Rostock.

ACTIVE NOT RECRUITING
Registry status
25,000 participants
Enrollment target
20
Study locations

Study Summary

Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the establishment of a candidate biomarker in the LRRK2-positive cohort.

Conditions Studied

Parkinson's Disease

Study Locations (20)

California

  • Pharmacology Research Institute - Encino
  • Neuro-Pain Medical Center - Fresno
  • University of California (UC) San Diego - La Jolla
  • Loma Linda University - Loma Linda
  • Pharmacology Research Institute - Los Alamitos
  • Pharmacology Research Institute - Newport Beach

Florida

  • Parkinson's Disease and Movement Disorder Center of Baco Raton - Baco Raton
  • Linfritz Research Institute - Coral Gables
  • Renstar Medical Research - Ocala
  • University of South Florida - Tampa
  • Vero Beach Neurology & Research Institute - Vero Beach

Illinois

  • Rush University Medical Center - Chicago
  • Northshore University HealthSystem - Evanston

New York

  • Dent Neurologic Institue - Amherst
  • Stony Brook University School of Medicine - Brookhaven

Arizona

  • Tucson Neuroscience Research - Tucson

Indiana

  • Indiana University, Department of Neurology - Indianapolis

Michigan

  • Michigan Institute for Neurological Disorders - Farmington Hills

Nevada

  • WR-CRCN - Las Vegas

Trial Details

FieldValue
Enrollment Target 25,000 participants
Start Date 2019-05-30
Est. Completion 2025-12-31

Sponsor

CENTOGENE GmbH Rostock

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03866603

The ClinicalTrials.gov registry entry for NCT03866603 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 25,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 482-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (5087% higher). The listed sponsor is CENTOGENE GmbH Rostock, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03866603 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT03866603 about?

NCT03866603 is a clinical study titled "Rostock International Parkinson's Disease Study (ROPAD)". Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the establishment of a candidate biomarker in the LRRK2-positive cohort.

What is the current status of trial NCT03866603?

This trial is currently active not recruiting. The enrollment target is 25,000 participants. The study started on 2019-05-30. Estimated completion is 2025-12-31.

What conditions does trial NCT03866603 study?

This clinical trial studies the following conditions: Parkinson's Disease.

Who is sponsoring clinical trial NCT03866603?

This trial is sponsored by CENTOGENE GmbH Rostock, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03866603 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.